Chembio Diagnostics Inc (NASDAQ:CEMI) CFO Neil A. Goldman acquired 14,815 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were bought at an average cost of $6.75 per share, with a total value of $100,001.25. Following the completion of the acquisition, the chief financial officer now owns 14,815 shares in the company, valued at $100,001.25. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of Chembio Diagnostics Inc (NASDAQ CEMI) opened at $7.80 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 2.19. Chembio Diagnostics Inc has a fifty-two week low of $5.05 and a fifty-two week high of $9.20.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royce & Associates LP grew its holdings in shares of Chembio Diagnostics by 367.6% in the fourth quarter. Royce & Associates LP now owns 102,400 shares of the company’s stock valued at $840,000 after purchasing an additional 80,500 shares in the last quarter. Benchmark Capital Advisors grew its holdings in shares of Chembio Diagnostics by 101.9% in the fourth quarter. Benchmark Capital Advisors now owns 66,417 shares of the company’s stock valued at $545,000 after purchasing an additional 33,517 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Chembio Diagnostics in the second quarter valued at $151,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Chembio Diagnostics by 55.4% in the second quarter. Wells Fargo & Company MN now owns 74,186 shares of the company’s stock valued at $449,000 after purchasing an additional 26,436 shares in the last quarter. 34.00% of the stock is owned by institutional investors and hedge funds.
About Chembio Diagnostics
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.